全文获取类型
收费全文 | 781篇 |
免费 | 51篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 20篇 |
妇产科学 | 10篇 |
基础医学 | 113篇 |
口腔科学 | 3篇 |
临床医学 | 99篇 |
内科学 | 226篇 |
皮肤病学 | 5篇 |
神经病学 | 37篇 |
特种医学 | 44篇 |
外科学 | 110篇 |
综合类 | 19篇 |
预防医学 | 62篇 |
眼科学 | 3篇 |
药学 | 54篇 |
肿瘤学 | 43篇 |
出版年
2023年 | 2篇 |
2022年 | 6篇 |
2021年 | 15篇 |
2020年 | 15篇 |
2019年 | 15篇 |
2018年 | 20篇 |
2017年 | 11篇 |
2016年 | 18篇 |
2015年 | 18篇 |
2014年 | 19篇 |
2013年 | 32篇 |
2012年 | 34篇 |
2011年 | 38篇 |
2010年 | 16篇 |
2009年 | 22篇 |
2008年 | 37篇 |
2007年 | 53篇 |
2006年 | 38篇 |
2005年 | 34篇 |
2004年 | 34篇 |
2003年 | 30篇 |
2002年 | 38篇 |
2001年 | 21篇 |
2000年 | 21篇 |
1999年 | 19篇 |
1998年 | 22篇 |
1997年 | 20篇 |
1996年 | 22篇 |
1995年 | 13篇 |
1994年 | 20篇 |
1993年 | 7篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 16篇 |
1989年 | 19篇 |
1988年 | 13篇 |
1987年 | 7篇 |
1986年 | 11篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 12篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1975年 | 3篇 |
1938年 | 1篇 |
1935年 | 1篇 |
1933年 | 1篇 |
排序方式: 共有850条查询结果,搜索用时 0 毫秒
71.
Pantoprazole-induced acute interstitial nephritis 总被引:3,自引:0,他引:3
Pantoprazole is a proton-pump inhibitor (PPI) that is commonly prescribed for the treatment of gastroesophageal reflux-related disorders. There are many documented side effects of PPIs. Here we report a case of acute interstitial nephritis, which developed after 6 weeks of treatment with pantoprazole. A 23-year-old man presented with acute renal failure requiring renal replacement therapy. Acute interstitial nephritis was diagnosed by renal biopsy and was successfully treated with corticosteroids and withdrawal of pantoprazole. Drug-induced acute interstitial nephritis can occur with PPIs such as pantoprazole and vigilance needs to be maintained. 相似文献
72.
73.
The adduct that would arise from cis opening of (+)-(1S,2R,3R, 4S)-3,4-dihydroxy-1,2-epoxy-benzo[c]phenan-threne (benzo[c]phenanthrene diol epoxide-2, where the benzylic hydroxyl group and the epoxide oxygen are trans) by the exocyclic N6-amino group of deoxyadenosine was incorporated at the marked site into four oligonucleotides, 5'-CAGA*TTTAGAGTCTGC-3', 5'-CAGTGCAGA*TTTAGAG-3', 5'-GTGCAGA*TTTAGA-3' and 5'-TGCAGA*TTTA-3'. The oligonucleotides were inserted into M13mp7L2 and the vector transfected into SOS-induced Escherichia coli SMH77 which were then plated on agar plates. The experiments reported here were designed to test the effect of the lesion position (the marked A in the sequences above) on the ligation efficiency of the insert and the frequency of failed constructs, as well as any possible effects on the mutagenic consequences of the lesion. The construct survival was estimated from the number of plaques formed following transformation, and mutation frequencies were estimated from sequencing of randomly picked plaques. Moving the adduct site to the middle of the sequence increased considerably the ligation efficiency regardless of the length of the inserted oligonucleotide, and changing the insert length or the adduct location did not markedly affect the frequency (40-58.6%) or distribution of mutations observed. Thus, so long as the local sequence (five or six bases surrounding the adduct) remains constant, the size of the oligonucleotide insert and the position of the adduct in it can be adjusted to give optimal ligation efficiency without altering the mutagenic consequences of the lesion. 相似文献
74.
75.
76.
The combination of high-dose busulfan (16 mg/kg) and 200 mg/kg cyclophosphamide is gaining increasing significance as a preparative regimen prior to autologous, syngeneic, or allogeneic marrow transplantation. A new regimen of high-dose busulfan in conjunction with a reduced dose of 120 mg/kg cyclophosphamide has recently been described as a preparative regimen prior to allogeneic transplantation. To determine the drug-related nonhematologic toxic effects of this new regimen without confounding factors associated with allogeneic transplantation, we conducted a pilot study using this new regimen in 20 patients with acute myeloid leukemia (AML) in first remission prior to autologous unpurged marrow transplantation. All patients experienced transient non-life-threatening acute drug-related toxicity with skin reactions in 20 (100%), nausea and vomiting in 20 (100%), oral mucositis in 18 (90%), hepatic functional impairment in 17 (85%), hemorrhagic cystitis in three (15%), and generalized seizures in two (10%) of these patients, respectively. Two procedural, fatal complications resulted from infectious causes that were not directly related to the speed of hematopoietic reconstitution or the toxicity of the preparative regimen. The 3-year event-free survival estimate (55% +/- 11%) and probability of leukemic recurrence (38% +/- 11%) attained with this new regimen in recipients of autografts in first remission of AML are promising and challenge comparisons with preparative regimens employing combinations of cytotoxic agents or total body irradiation (TBI). 相似文献
77.
Arcese W; Goldman JM; D'Arcangelo E; Schattenberg A; Nardi A; Apperley JF; Frassoni F; Aversa F; Prentice HG; Ljungman P 《Blood》1993,82(10):3211-3219
We studied the clinical course of 130 chronic myeloid leukemia (CML) patients (89 males and 41 females) in the European Bone Marrow Transplantation Group (EBMT) registry who received transplants before January 1, 1988 and who subsequently had evidence of recurrent leukemia. All patients had received a pretransplant conditioning regimen including total body irradiation (TBI). The first evidence of relapse was cytogenetic only in 74 (57%) patients and hematologic in 56 (43%). The overall actuarial survival from relapse was 36% at 6 years, with a significantly higher proportion of survivors among female patients (53% v 30%; P < .002). In univariate analysis, the 6-year probability of survival was 52% for patients with cytogenetic relapse and 30% for patients relapsing in chronic phase (CP), while no patient who relapsed in advanced phase (AP or BC) survived more than 3.5 years from relapse (P < .0001). The actuarial survival of patients relapsing before 6 months, between 6 and 12 months, and later than 12 months after transplant was 27%, 26%, and 45%, respectively (P < .002). Among patients with cytogenetic relapse, partial or complete disappearance of Ph-positive cells occurred in 40% of untreated patients and in 42% of those treated with interferon (IFN). However, IFN therapy significantly delayed progression toward hematologic disease. Cytogenetic responses were observed in 25% of patients who received IFN for relapse into CP, while only one minor cytogenetic response was reported in patients on conventional chemotherapy. For patients presenting with cytogenetic relapse as well as for those in hematologic relapse, IFN therapy significantly improved the 2-year probability of survival. However, long-term survival for IFN-treated patients in either group was not different from long-term survival in comparable patients not receiving IFN therapy. Twenty-nine patients of this series underwent a second bone marrow transplant (BMT) and the projected survival at 4 years after the second transplant is 28%. In multivariate Cox regression analysis, four factors remained significantly associated with survival: disease phase at relapse (P < .0001), duration of time interval from BMT to relapse (P = .0001), interferon therapy at relapse (P = .0024), and patient sex (P = .0032). This retrospective study provides evidence that some patients who relapse after BMT may benefit from treatment with IFN; a second BMT may offer the chance of cure. Data from this analysis may be useful in designing future prospective trials on posttransplant CML relapse. 相似文献
78.
79.
The paper discusses the role of unconventional methods in palliative care of cancer patients. A review of the literature as well an interview of the palliative care units of Thuringia showed that problems increase regarding CAM during ongoing cancer disease. The art of palliative care is to minimize different therapies without a lost of compliance in our patients and their relatives. The selected use of proven CAM methods may effectively support this aim. 相似文献
80.